Dr. Freytag currently serves as a member of the board of directors for four health care companies: ARCA biopharma, Inc., GlobeImmune, Inc., BaroFold, Inc., and BiOptix Inc. Dr. Freytag was Chairman and Chief Executive Officer of Aspreva Pharmaceuticals from July 2007 until its merger with Galenica AG in January 2008. Prior to Aspreva, Dr. Freytag was President, Chief Executive Officer and Chairman of the Board of Directors of Myogen, Inc. from July 1998 until Myogen was acquired by Gilead Sciences in November 2006. From November 2006 through June 2007 Dr. Freytag served as Senior Advisor to Gilead. From October 1994 to May 1998, Dr. Freytag was a Senior Vice President at Somatogen, Inc. Prior to Somatogen, he was President of Research and Development at Boehringer Mannheim Corporation, an international healthcare company, from May 1990 to September 1994. Previously, Dr. Freytag spent ten years with DuPont in various research and business positions in the Medical Products Department. Dr. Freytag is also a member of the Board of Trustees of Colorado University Foundation, a member of the Advisory Council for the Bard Center for Entrepreneurship, University of Colorado Denver Business School, and a member of the Board of the Deming Center for Entrepreneurship, Leeds School of Business, University of Colorado. Dr. Freytag received a B.S. from Purdue University and a Ph.D. in biochemistry from the University of Kansas Medical Center.